PDB107 Cost-Effectiveness of Empagliflozin (Jardiance®) 10 Mg And 25 Mg Administered As An Add-on To Metformin Compared To Other Sodium-Glucose Co-Transporter 2 Inhibitors (Sglt2is) for Patients With Type 2 Diabetes Mellitus (T2dm) In The UK  by Aguiar-Ibáñez, R. et al.
A350  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  
0.377 QALYs (95% CI: -0.227 to 0.754) and cost savings of € 264 (95% CI: -€ 1,879 to € 
2,768).. At a willingness-to-pay threshold of € 30,000 per QALY gained, SAXA strategy 
had an 82% probability to be cost-effective. Compared to TZD add-on to MET plus SU, 
the triple therapy with SAXA reached an incremental cost-effectiveness ratio of € 2,610 
per QALY gained. ConClusions: Saxagliptin was predicted to be a cost-effective 
option in Spain when a new drug needs to be added in T2DM patients inadequately 
controlled with metformin and sulphonylurea alone.
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objeCtives: To assess the cost-effectiveness of dapagliflozin, a sodium-glucose 
co-transporter-2 (SGLT-2) inhibitor versus dipeptidyl peptidase-4 inhibitor (DPP4i) 
both added on top of insulin, or compared to insulin alone (±oral anti-diabetes 
agents) for patients who are inadequately controlled on insulin strategy. Methods: 
The CARDIFF diabetes model was used. Clinical inputs were derived from a rand-
omized clinical trial comparing dapagliflozin add-on to insulin with insulin alone, 
and network-meta-analysis for the comparison with DPP4i. Together with United 
Kingdom Prospective Diabetes Study (UKPDS) equations, the model predicts disease 
progression and the number of micro- and macro-vascular complications, along 
with diabetes-specific and all-cause mortality. The perspective of the Spanish health 
care payer was adopted over a lifetime horizon. Costs and utilities were assigned 
to the appropriate model parameters to calculate total Quality-Adjusted-Life-Years 
(QALYs) and total costs. Deterministic and probabilistic sensitivity analyses were 
conducted. Results: Compared to insulin alone, dapagliflozin added to insulin was 
associated with 0.698 incremental QALYs (95%CI: 0.442; 1.211) at an additional cost 
of € 1,508 (95%CI: € 611; € 1,517), resulting in an incremental cost-effectiveness ratio 
(ICER) point estimate of € 2,159/QALY. Dapagliflozin was found to dominate DPP4i 
add-on to insulin, being associated with slightly less costs (-€ 51; 95%CI: -€ 913; € 553) 
and higher QALYs (0.168; 95%CI: -0.007; 0.417). At a willingness-to-pay threshold of 
€ 20,000/QALY, the dapagliflozin strategy was estimated to have a 100% probability 
of being cost-effective when compared to the insulin alone, and a 98% probability 
when compared to the DPP4i strategy. These findings were shown to be robust to 
variation in range of model parameters. ConClusions: Dapagliflozin added on 
top of Insulin was predicted to be a cost-effective (vs. insulin alone) and cost sav-
ing (vs DPP4i) alternative in Spain in combination with insulin for patients who are 
inadequately controlled with insulin treatment regimens.
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objeCtives: Tolvaptan is a selective vasopressin V2-receptor antagonist indicated 
for the treatment of adult patients with hyponatraemia (HN) secondary to syndrome 
of inappropriate antidiuretic hormone secretion (SIADH). To date there have been 
no published economic evaluations assessing the cost effectiveness of tolvaptan 
in this indication. The aim of this study was to evaluate the cost effectiveness 
of tolvaptan versus no active treatment (NAT) from a Swedish societal perspec-
tive. Methods: The economic evaluation considers a hypothetical population of 
individuals with HN secondary to SIADH who have either failed to respond to fluid 
restriction or for whom the use of fluid restriction is not suitable. The analysis con-
siders three clinically relevant patient populations within the SIADH indication: ‘all 
SIADH’, small-cell lung cancer (SCLC) and pneumonia. A discrete event simulation 
was developed to model the progression of individuals through multiple inpatient 
admissions over a 30 day time horizon (180 days in the SCLC scenario). Key sources 
of evidence included randomised controlled trials (SALT I & II) and observational 
data sources. Unit costs were collected from publicly available sources. Utility values 
were obtained from mapping the SF-12 scores from the SALT I & II trials to EQ-5D. 
The primary outcome of the analysis was the incremental cost-effectiveness ratio 
(ICER) expressed as a cost per quality-adjusted life-year (QALY). Results: In the 
‘all SIADH’ population tolvaptan was associated with reduced costs (SEK 5,778) and 
increased QALYs (0.0019) versus NAT and was therefore dominant. In the SCLC and 
pneumonia subgroups tolvaptan was also associated with reduced costs and QALY 
improvements. The results were most sensitive to the duration of tolvaptan treat-
ment and the assumptions around duration of hospitalisation. ConClusions: In 
all populations considered (all SIADH, SCLC and pneumonia) tolvaptan was domi-
nant compared to NAT being associated with reduced costs and increased QALYs.
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objeCtives: To assess the cost-effectiveness of the novel SGLT2is empagliflozin 10mg 
and 25mg compared to other SGLT2is (canagliflozin 100mg, canagliflozin 300mg, and 
dapagliflozin 10mg) when administered as an add-on to metformin for the treat-
ment of patients with T2DM in the UK. Methods: A micro-simulation model was 
developed, based on the United Kingdom Prospective Diabetes Study (UKPDS68) and 
the Januvia Diabetes Economic (JADE) model, to estimate long-term diabetes-related 
complications, QALYs and costs in a cohort of T2DM patients initiating dual therapy. 
The model was populated with the results of a network meta-analysis that estimated 
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objeCtives: To evaluate the economic burden among patients diagnosed with 
Cushing’s disease (CD) in the U.S. Medicaid program. Methods: Patients diagnosed 
with CD (International Classification of Disease, 9thRevision, Clinical Modification 
(ICD-9-CM) diagnosis code 255.0) were identified using U.S. Medicaid data from 01 
January 2008 through 31 December 2010. The initial diagnosis date was designated 
as the index date. A matching comparator cohort was created including patients of 
the same age, race and gender but without a CD diagnosis, and a randomly-chosen 
index date to minimize selection bias. Patients in both cohorts were required to be 
age ≥ 18 years, with continuous medical and pharmacy benefits for 1 year pre- and 
1 year post-index date. One-to-one propensity score matching (PSM) was used to 
compare health care costs and utilizations during the follow-up period between the 
diseased and comparison cohorts, and was adjusted for baseline demographic and 
clinical characteristics. Results: After risk adjustment by PSM, a total of 340 patients 
in each cohort were matched. CD patients had significantly higher health care utili-
zation, including inpatient admissions (36.18% vs. 12.53%, p< 0.0001) and long-term 
care (5.29% vs. 2.06%, p< 0.05), other service (100% vs. 94.12%, p< 0.0001) and pharmacy 
visits (84.41% vs. 78.24%, p< 0.05), compared to those without the disease. CD patients 
incurred significantly higher inpatient ($4,688 vs. $1,139, p< 0.05) and pharmacy costs 
($4,054 vs. $2,100, p< 0.001) compared to those without CD. Long-term care and other 
service costs incurred were higher for CD patients, compared to comparison patients, 
but were not statistically significant. ConClusions: In the current study, CD patients 
in the U.S. Medicaid program had a higher burden of illness in terms of health care 
resource utilization and costs, compared to those without a CD diagnosis.
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objeCtives: The Dose Adjustment For Normal Eating (DAFNE) structured education 
programme is shown to be effective both in terms of clinical outcomes and cost-
effectiveness outcomes in the treatment of T1DM. DAFNEPlus aims to revise the 
DAFNE 5-day curriculum based on psychological and sociological findings in DAFNE, 
input from DAFNE graduates and emerging knowledge around behavioural science 
and technological developments. The current suggested primary endpoint is for the 
DAFNEplus programme to have an additional 20% DAFNE participants (70% in total) 
achieve either, (a) a reduction of at least 0.5% in HbA1c, or (b) to have an HbA1c below 
7.5% (58.5 mmol/mol), at 12 months. This paper undertakes pre-trial what-if cost-
effectiveness analyses concerning the DAFNEPlus programme, which aim to be use-
ful both in the design of the intervention itself and of the proposed trial. Methods: 
The Sheffield Type 1 Diabetes Policy Model is an individual patient-level simulation 
model of T1DM. It includes long-term microvascular (retinopathy, neuropathy and 
nephropathy) and macrovascular (myocardial infarction, stroke, revascularization 
and angina) diabetes-related complications and acute adverse events (severe hypo-
glycaemia and diabetic ketoacidosis). Econometric methods were used to obtain 
the target level of HbA1c responders in the DAFNEPlus arm. Results: DAFNEplus 
would be considered as cost-effective if the additional spending on the intervention 
would be limited to £455-£751 per patient per year, depending on the assumptions 
on the length of maintenance period for the HbA1c benefit and the target HbA1c 
responder endpoint (70% in total) being achieved in the future trial. To achieve a 
more favourable cost-effectiveness probability of 80%, for example, the additional 
per patient per year cost should be restricted to £393-£574 range. ConClusions: 
Pre-trial modelling has enabled a clear understanding of the threshold range for the 
annual cost of DAFNEplus, which is still being designed, in order to be considered 
as cost-effective at the £20,000/QALY threshold.
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objeCtives: In patients with type 2 diabetes mellitus (T2DM), when blood glucose 
is not adequately controlled by the combination of metformin (MET) and sulphony-
lurea (SU), the clinician has to choose between adding a third oral drug or starting 
insulin therapy. The objective of this study was to assess the cost-effectiveness in the 
Spanish setting of adding saxagliptin (SAXA) to MET and SU, compared to adding basal 
insulin (INS). Additionally, the SAXA strategy was compared with a thiazolidinedione 
(TZD), also added on top of MET and SU. Methods: The published and validated 
CARDIFF long-term diabetes model was used to estimate the direct medical costs and 
quality-adjusted life years (QALYs) associated with each strategy. Clinical inputs were 
obtained from a network meta-analysis. Based on the United Kingdom Prospective 
Diabetes Study equations, the model predicted disease progression and occurrence 
of micro- and macro-vascular complications, including mortality. Costs and utilities 
were applied to complications, hypoglycaemias and body mass index changes. The 
perspective of the Spanish Healthcare System was adopted over a lifetime horizon, 
at a discount rate of 3% (costs and health outcomes). Univariate and probabilistic 
sensitivity analyses were conducted. Results: SAXA add-on to MET plus SU resulted 
in a dominant strategy compared to INS add-on to MET plus SU, providing a gain of 
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objeCtives: To assess the cost-effectiveness of the SGLT2is empagliflozin 10mg 
and 25mg compared to other SGLT2is (canagliflozin 100mg and canagliflozin 
300mg) when administered as an add-on to MET+SU in patients with T2DM in 
the UK. Methods: Long-term diabetes-related complications, QALYs, and costs 
were estimated for T2DM patients failing MET+SU. A micro-simulation model was 
developed based on the United Kingdom Prospective Diabetes Study (UKPDS68) and 
the Januvia Diabetes Economic (JADE) model. A network meta-analysis comparing 
efficacy and safety across SGLT2is was used to populate the model. Data gaps were 
completed with information derived from published sources, including previous 
cost-effectiveness models. Costs and QALYs were estimated over a patients’ lifetime 
from the UK National Health Service perspective. Results: Empagliflozin 10mg 
attained the highest QALYs (6.991, compared to 6.98 for canagliflozin 100mg, 6.978 
for empagliflozin 25mg and 6.976 for canagliflozin 300mg) due to slightly better 
HbA1c, SBP and weight control, and a small number of non-severe hypoglycae-
mias, compared to higher doses. Canagliflozin 300mg was the most costly strategy 
(£32,087, vs. £31,217 for canagliflozin 100mg, £31,409 for empagliflozin 10mg and 
£31,557 for empagliflozin 25mg). Therefore, empagliflozin 10mg dominated both 
canagliflozin 300mg and empagliflozin 25mg, and resulted in an incremental cost-
effectiveness ratio of £17,445 per QALY gained vs. canagliflozin 100mg. However, 
incremental QALY and cost differences were not significant based on 95% percentile 
confidence intervals. These results remained robust when sensitivity analyses were 
conducted, including utilities, adverse events, discontinuation, modelling of weight, 
impact of BMI, duration of effect, time horizon and discount rates. ConClusions: 
Differences in QALYs and costs between SGLT2is as add-ons to MET+SU were minor. 
On average, empagliflozin 10mg resulted to be the most cost-effective option for 
T2DM patients failing MET+SU when commonly accepted thresholds in the UK 
were considered, with an incremental cost per QALY of £17,445 compared to cana-
gliflozin 100mg.
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objeCtives: Diabetic Foot Syndrome (DFS) is a serious and common complica-
tion of diabetes, often leading to limb amputation and disability. Disability and 
productivity loss in patients with DFS can generate significant indirect costs and 
potentially significant economic consequences. The purpose of the study is to esti-
mate productivity loss and indirect costs associated with foot ulceration in patients 
with DFS. Methods: We conducted a prospective survey in a population of DFS 
patients with foot ulceration. Loss of productivity was measured with a modified 
WPAI questionnaire. Indirect costs of both absenteeism and presenteeism were 
estimated using the human capital approach on the basis of the measure of gross 
value added per employee. Results: Nearly one third of respondents (32%) declared 
that foot ulceration was the direct reason why they abandoned their professional 
activity. 40% and 34% of respondents, respectively, were forced to limit or change 
their professional activity at some point in the past because of the foot ulceration. 
More than 40% of respondents who changed or limited their professional activity 
because of the foot ulceration experienced reduction in earnings by 22.9% on aver-
age. Mean absenteeism was estimated at 32.63% of the nominal working time, while 
presenteeism was estimated at 23.48% of real working time. Total annual indirect 
costs associated with productivity loss amounted to EUR 170.8 million, including 
EUR 117.3 million of the costs of sickness absence and EUR 53.5 million of the costs 
of presenteeism. ConClusions: Foot ulceration in patients with DFS is a com-
mon cause why patients are forced to give up or change their professional activity, 
which usually leads to a reduction in earnings. Indirect costs associated with foot 
ulceration in DFS impose a significant burden on the Polish economy. There is no 
rationale that would clearly link productivity loss associated with ulceration in DFS 
and the ulceration severity.
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objeCtives: Insulin administration in the acute care setting is an integral com-
ponent of inpatient diabetes management. The current method of administration 
in acute care settings is by vial and syringe. The aim of this study was to evalu-
ate the impact of insulin pen implementation in the acute care setting on patient 
and health care worker safety, and health resource utilization (HRU). Methods: A 
review of published literature was conducted to identify how insulin pen devices 
in the acute care setting may impact inpatient diabetes management. Additionally, 
nurse researchers from the McGill University Health Centre conducted a pilot study 
in a 52-bed unit to quantify this impact in a local context. Together, the results of 
the literature search and the pilot served as the inputs to an economic model, 
developed in Excel v14. Costs for the volume of insulin dispensed, injection sup-
plies, needlestick injury management, and nursing labour were assessed. Results: 
Previous published studies have revealed that insulin pen devices have the poten-
tial to improve inpatient management through better glycemic control, increased 
adherence and improved self-management education. The combined results from 
the literature and pilot indicate that moving from vial and non-safety syringe to 
a passive safety pen in acute care results in total estimated annual cost savings 
of $43,339.66, and 191.42 hours of nursing time saved (site with 52 beds dedicated 
to patients with diabetes). Cost savings from the adoption of a passive safety 
insulin pen were predicted based on reductions in insulin volume and needle-
stick injuries. For an institution of similar size using safety syringes, the move to a 
the comparative efficacy and safety across SGLT2is. Data gaps were completed with 
information derived from published sources, including previous cost-effectiveness 
analyses. The UK National Health Service (NHS) perspective was considered to esti-
mate costs and QALYs over a patients’ lifetime. Results: There were small differ-
ences in efficacy and safety across SGLT2is, which resulted in minor QALY and cost 
differences across treatment combinations. On average, empagliflozin 25mg obtained 
incremental QALYs of 0.029 versus dapagliflozin 10mg and 0.019 versus canagliflozin 
100mg, and incremental costs of £178 and £86, respectively, whereas both canagli-
flozin 300mg and empagliflozin 10mg were dominated by empagliflozin 25mg. This 
resulted in an incremental cost-effectiveness ratio (ICER) of £4,858 per QALY gained 
with empagliflozin 25mg vs. canagliflozin 100mg. However, the differences across 
treatments were not significant when 95% percentile confidence intervals were 
considered. These results were robust to a number of sensitivity analyses including 
a 10-year time horizon, BMI impact, discount rates and parameter values related 
to utilities, disutilities, adverse events, and discontinuation rates. ConClusions: 
Overall, differences in QALYs and costs were minor between SGLT2is used as add-on 
to metformin in UK T2DM patients. On average, empagliflozin 25mg was the most 
cost-effective strategy, with an ICER of £4,858 per QALY gained vs. canagliflozin 100mg.
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objeCtives: A small, minimally-invasive flash glucose monitor (FGM) has recently 
been developed. Arm sensors worn up to 14 days interact with a hand-held reader 
to convey 8 hours of continuous glucose level data. The reader stores data, com-
municating glucose control via trend charts. Economic evaluation of FGM vs. con-
ventional blood glucose monitoring (BGM) has not been conducted. This analysis 
estimates potential cost-effectiveness of using FGM in UK insulin-treated type 2 
diabetes mellitus (T2DM) patients. Methods: The IMS Core Diabetes Model (CDM) 
was used for analyses, assuming a lifetime horizon (40 years). Patient characteristics 
were based on early FGM feasibility trial data. Effectiveness was measured in life 
years (LY) and quality-adjusted life years (QALY), with assumptions around FGM 
effectiveness based on expected benefits of use. These include: a) lower HbA1c by 
0.35%-0.5% compared to BGM over the horizon; b) utility improvement due to fewer 
finger pricks of 0-0.03; c) minor hypoglycaemic event rate reduction of 0% or 50% 
compared to BGM due to potential improved glycaemic control. Cost data (direct 
costs only) were extracted from published literature and government sources, and 
inflated to 2013 GBP. Incremental cost-effectiveness ratios (ICERs) were estimated, 
and threshold analysis was performed to estimate potential total FGM sensor costs 
for each scenario. Results: Based on assumptions above, the ICER for FGM vs. 
BGM ranges from £10,034-£29,068/QALY. With 0.5% HbA1c improvement, 0.01 util-
ity benefit, and no difference in hypoglycaemic events, the ICER is £17,808/QALY. 
Assumptions around utility improvement have a larger ICER impact than HbA1c 
benefit or change in minor hypoglycaemic events. Threshold analysis shows that 
with a conventional ICER threshold (£30,000/QALY), £14,606-£27,956 can be spent on 
sensors over a lifetime across scenarios. ConClusions: Using an alternate glucose 
monitoring method could be cost-effective across a variety of clinical benefit and 
cost assumptions in T2DM (T1DM analysis forthcoming).
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objeCtives: To evaluate the cost-effectiveness of canagliflozin, an active inhibitor 
of sodium glucose co-transporter – 2 (SGLT2), in triple therapy of diabetes as add-
on to metformin and sulfonylurea compared to NPH insulin in combination with 
oral antidiabetics. Canagliflozin in clinical trial results showed effective glucose 
reduction, along with other benefits in diabetes treatment including weight loss 
and SBP reduction. Cost effectiveness analyses were conducted in the Polish set-
ting from a public perspective in accordance with guidelines of Polish HTA Agency 
(PolAHTA). Methods: The IMS CORE Diabetes Model was used to evaluate the 
cost-effectiveness of canagliflozin in triple therapy versus NPH insulin using Polish-
specific data, where available. Clinical data were derived from mixed treatment 
comparison analysis of published studies, as there is no head to head trial com-
paring canagliflozin with NPH insulin. Direct costs were reported in Polish zloty 
and an annual discount rate of 5% and 3.5% were applied on costs and effects 
respectively. Results: In a triple therapy as add-on to metformin and sulfonylurea 
canagliflozin is a cost- effective treatment option in comparison with NPH insulin 
with ICERs of 4 477 z³ and 69 081 z³ for canagliflozin 100 mg and 300 mg respec-
tively. Associated QALY gains were 0,084 and 0,106. Both results are below defined 
in Polish reimbursement act cost-effectiveness threshold. ConClusions: These 
results suggest that adding Canagliflozin to dual therapy versus insulin intensifica-
tion in patients inadequately controlled with MET+ SU would be a more efficient 
use of health care resources in the Polish setting.
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